Sponsor or institution

Clinical trials and research at Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

• 9Clinical trials
• 31Countries

Newest trials

All recruiting trials (9)

• Healthy-donor CD19-targeted allogeneic CAR T-cell therapy for severe, treatment-resistant autoimmune diseases

  This will test whether an infusion of healthy-donor CD19-targeted CAR T cells is safe and can help people with severe, treatment-resistant autoimmune diseases such as lupus, inflammatory myopathy, or systemic sclerosis.

  Recruiting at 19 sites Phase 1 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Boston, Massachusetts and 27 other locations · NCT07115745

• Lisocabtagene maraleucel (liso-cel) as first-line treatment for adults with transplant-ineligible primary central nervous system lymphoma

  This will test whether lisocabtagene maraleucel (liso-cel), given with a high-dose methotrexate–based regimen, is safe and works as first treatment for adults with primary CNS lymphoma who cannot have a transplant.

  Recruiting at 36 sites Phase 2 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Aurora, Colorado and 39 other locations · NCT07015242

• Long-term safety of lisocabtagene maraleucel in patients with relapsed follicular lymphoma

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed follicular lymphoma who have already received it.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06794268

• Long-term safety and effectiveness of lisocabtagene maraleucel for Mantle Cell Lymphoma

  This study looks at how safe and effective the treatment lisocabtagene maraleucel is for people with relapsed or refractory Mantle Cell Lymphoma over a long period of time.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788652

• Long-term safety of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788639

• Comparing BMS-986393 with standard treatments for relapsed multiple myeloma

  This study is testing a new drug called BMS-986393 to see if it works better than standard treatments for adults with relapsed multiple myeloma who haven't responded to lenalidomide.

  Recruiting at 122 sites Phase 3 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama and 140 other locations · NCT06615479

• CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study is testing a new CAR T cell therapy to see if it can help adults with multiple myeloma who haven't had success with other treatments.

  Recruiting at 49 sites Phase 2 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama and 51 other locations · NCT06297226

• Assessing BMS-986453 for treating relapsed multiple myeloma

  This study is testing a new treatment called BMS-986453, combined with other medications, to see if it can help people with relapsed multiple myeloma who haven't responded to previous therapies.

  Recruiting at 18 sites Phase 1 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama and 18 other locations · NCT06153251

• Evaluating a new treatment for relapsed and refractory multiple myeloma

  This study is testing a new treatment combination for people with relapsed or hard-to-treat multiple myeloma to see if it is safe and effective.

  Recruiting at 17 sites Phase 1 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama and 18 other locations · NCT06121843

Quick answers

How many clinical trials run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company are recruiting right now?

9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in United States (9 trials), France (4 trials), Germany (4 trials), Canada (3 trials), Australia (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →